Matthew Lang is Chief Business Officer of Lyell Immunopharma, Inc.. Currently has a direct ownership of 50,000 shares of LYEL, which is worth approximately $61,000. The most recent transaction as insider was on Feb 09, 2024, when has been sold 50,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 50K
0% 3M change
n/a 12M change
Total Value Held $61,000

Matthew Lang Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 09 2024
BUY
Grant, award, or other acquisition
-
50,000 Added 50.0%
50,000 Common Stock

Also insider at

MYOV
Myovant Sciences Ltd. Healthcare
ML

Matthew Lang

Chief Business Officer
Brisbane, CA

Track Institutional and Insider Activities on LYEL

Follow Lyell Immunopharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LYEL shares.

Notify only if

Insider Trading

Get notified when an Lyell Immunopharma, Inc. insider buys or sells LYEL shares.

Notify only if

News

Receive news related to Lyell Immunopharma, Inc.

Track Activities on LYEL